Otonomy Competitors and Similar CompaniesClear all
Otonomy's competitors and similar companies include Seed Health, BeyondSpring, Vertex Pharmaceuticals and Biogen.
 Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. |  Seed Health Seed Health is a microbial sciences company developing applications of bacteria to impact human and environmental health.
|  BeyondSpring BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. |  Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | |
Founding Date | Founding Date 2008 | Founding Date 2016 | Founding Date 2010 | Founding Date 1989 | Founding Date 1978 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Venice, US HQ | Locations Florham Park, US HQ | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | |
Employees | Employees 49 | Employees 234 | Employees 4014% increase | Employees 5,40013% increase | Employees 7,605 |
Valuation ($) | Valuation ($) 5.3 m | Valuation ($) N/A | Valuation ($) 89.4 m | Valuation ($) 121.4 b | Valuation ($) 26.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $125k (FY, 2021) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $12b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods $370k (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods $1.7b (FY, 2025) | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $10.4b (FY, 2025) | Gross profit $7.5b (FY, 2025) |
Net income | Net income ($51.2m) (FY, 2021) | Net income N/A | Net income ($16.7m) (FY, 2024) | Net income N/A | Net income $1.3b (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2024) |
Phase II Trials Products | Phase II Trials Products 2 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2017) | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2019) | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) |
Pre-Clinical Phase Products | Pre-Clinical Phase Products 1 (FY, 2016) | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 5 (FY, 2019) | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A |
Products | Products 1 (FY, 2016) | Products N/A | Products N/A | Products 6 (FY, 2022) | Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 153.4m | Total funding raised $ 40m | Total funding raised $ 36.1m | Total funding raised $ 2.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Seed Health
HQ
Venice, US
Employees
234
Seed Health is a microbial sciences company developing applications of bacteria to impact human and environmental health.
View companyBeyondSpring
HQ
Florham Park, US
Employees
40↑ 14% increase
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies.
View companyVertex Pharmaceuticals
HQ
Boston, US
Employees
5,400↑ 13% increase
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company